The REMS Industry Consortium (RIC) brings together the Risk Evaluation and Mitigation Strategies industry to advance patient safety and innovation in the implementation of new drugs and biologics. By joining RIC, you can gain knowledge, experience, and professional affiliations that will put you at the forefront of REMS industry advancements. Through RIC networking opportunities, you will make vital connections with other professionals in this space who share your desire for collaboration and guidance in addressing industry challenges.

Membership dues for pharmaceutical manufacturers for 2024 are:

Founding Members: $78,000
Board Members (Board Seat and 5 or more participants from organization): $50,000
Enterprise Members (5 or more participants from organization): $15,000
Group Members (1-4 participants from organization): $5,000 

Membership Benefits


Current RIC Members include:
Amneal Pharmaceuticals
Aimmune Therapeutics, a Nestle Health Sciences Company
Apellis Pharmaceuticals, Inc.
Ascend Laboratories LLC, a subsidiary of Alkem Laboratories Ltd
AstraZeneca Pharmaceuticals LP
Bristol Myers Squibb
Chinook Therapeutics, Inc.
Endo Pharmaceuticals
Gilead Sciences
Hikma Pharmaceuticals USA Inc.
Johnson & Johnson Innovative Medicine
Jazz Pharmaceuticals
Mayne Pharma
Pfizer Inc.
Sun Pharma
Tasman Pharma Inc.
Teva Pharmaceuticals
Zydus Pharmaceuticals USA Inc.

Current Industry Partners include:

APCER Life Sciences
Axian Consulting, Ltd.
Invaryant, LLC
Metis Consulting Services, Inc.
MMS Holdings Inc
North Highland
Shephard Safety Services at Two Labs
Syneos Health
United BioSource, LLC
Venebio Group, LLC